Intraosseous Versus Intravenous Vancomycin in Below-Knee Amputation for Ischemic Diabetic Foot
Key facts
- Who runs it
- Başakşehir Çam & Sakura City Hospital
- Where
- Türkiye1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 4
- People taking part
- 40 people enrolled
- Started
- 6 Aug 2025
- Ended
- 21 Jun 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Intraosseous Vancomycin
- Intravenous Vancomycin
- Record updated
- 10 July 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (13)Hide the full registry criteria
Who can take part
- Age 18 years or older
- Diagnosis of diabetes mellitus
- Diabetic foot infection with distal ischemia
- Scheduled to undergo below-knee amputation
- Absence of a feasible further revascularization option, as determined by the cardiovascular surgery and interventional radiology teams
- Adequate circulation at and proximal to the planned below-knee amputation level for stump healing
- Ability to provide written informed consent
Who cannot take part
- Systemic vancomycin use within 48 hours before surgery
- Previous Syme amputation or more proximal amputation
- Documented allergy or hypersensitivity to vancomycin or cephalosporins
- Dialysis dependence
- Planned amputation at a level other than below the knee
- Incomplete perioperative pharmacokinetic sampling
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This randomized clinical trial compared two routes of vancomycin administration in patients undergoing below-knee amputation for ischemic diabetic foot infection. Patients with diabetic foot infection and impaired lower-extremity circulation may have reduced delivery of intravenously administered antibiotics to the amputation stump. Intraosseous administration may increase local antibiotic exposure at the surgical site while reducing systemic exposure.
Read full original descriptionShow less
Participants were randomly assigned to receive either intraosseous vancomycin or intravenous vancomycin before skin incision. The study evaluated vancomycin concentrations in amputation stump subcutaneous tissue, simultaneous serum vancomycin concentrations, tissue-to-serum concentration ratios, inflammatory marker trajectories, early wound outcomes, pain scores, drain output, reintervention, mortality, renal safety, and systemic adverse events through postoperative follow-up.
The 2 groups in the trial
- Intraosseous VancomycinTreatment being tested
Participants received 500 mg of vancomycin diluted in 100 mL of 0.9% normal saline via intraosseous administration into the proximal tibial metaphysis immediately before skin incision.
- Intravenous VancomycinExisting treatment, for comparison
Participants received 500 mg of vancomycin intravenously at the same preincision time point before below-knee amputation.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Does Intraosseous Compared With Intravenous Vancomycin Alter Local Exposure, Systemic Safety, and Early Outcomes in Patients With Ischemic Diabetic Foot Undergoing Below-knee Amputation? A Randomized Trial
- Record updated
- 10 July 2026